Pancreatic Cancer and Venous Thromboembolism

Teagan Prouse,Mohammad A. Mohammad,Sonali Ghosh,Narender Kumar,Ma. Lorena Duhaylungsod,Rinku Majumder,Samarpan Majumder

DOI: https://doi.org/10.3390/ijms25115661

IF: 5.6

2024-05-24

International Journal of Molecular Sciences

Abstract:Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, primarily venous thromboembolism (VTE). Of all cancer types, PDAC is associated with the highest risk of developing VTE. Hypoxia in a PDAC tumor microenvironment also elevates thrombotic risk. Direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) are used only as thromboprophylaxis in PDAC. However, a precision medicine approach is recommended to determine the precise dose and duration of thromboprophylaxis in clinical setting.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the relationship between pancreatic ductal adenocarcinoma (PDAC) and venous thromboembolism (VTE), and how to improve the prognosis of patients by identifying and managing these risk factors. Specifically, the paper focuses on the following aspects:

1. **Relationship between pancreatic ductal adenocarcinoma (PDAC) and venous thromboembolism (VTE)**:
- Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, and its treatment effect is far from satisfactory. Surgery is still the main curative method. However, PDAC tumor progression is associated with strong activation of the coagulation system. In particular, cancer - associated thrombosis (CAT) is an important risk factor for PDAC.
- Studies have found that the risk of VTE in PDAC patients within one year after diagnosis is significantly higher than that in other cancer patients. Therefore, understanding the relationship between PDAC and VTE is crucial for improving the prognosis of patients.

2. **Tumor microenvironment and hypercoagulable state**:
- The tumor microenvironment plays a key role in the hypercoagulable state of cancer patients. The two - way communication between tumor cells and the dynamic tumor microenvironment (TME) activates Virchow's triad (coagulation activation, vascular injury, and stasis), thereby promoting CAT or increasing the risk of VTE.
- This hypercoagulable state not only affects blood parameters, such as the activity of red blood cells and platelets and their markers, but also involves changes in coagulation factors and anticoagulation factors.

3. **Risk assessment and preventive measures**:
- The paper discusses multiple risk assessment models (RAMs), such as the Caprini score and the Khorana score, for assessing the VTE risk in cancer patients. In particular, the Khorana score is analyzed in detail in predicting the VTE risk in PDAC patients.
- Through these assessment tools, high - risk patients can be better identified, and appropriate preventive measures can be taken, such as using direct oral anticoagulants (DOACs) or low - molecular - weight heparin (LMWH) for thrombosis prevention.

4. **Clinical significance**:
- Early detection and management of VTE are of great significance for improving the survival rate and quality of life of PDAC patients. The paper emphasizes the necessity of adopting a precision medicine approach in clinical practice to determine the precise dose and duration of thrombosis prevention.

In summary, this paper aims to provide a scientific basis by in - depth exploration of the relationship between PDAC and VTE to guide risk assessment and preventive measures in clinical practice, thereby improving the prognosis of PDAC patients.